

Protalix BioTherapeutics, Inc.  
Form 8-K  
June 27, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 26, 2007

**Protalix BioTherapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

Florida	000-27836	65-0643773
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
<b>2 Snunit Street Science Park POB 455 Carmiel, Israel 21000</b>		

(Address of principal executive offices) (Zip Code)

(Former Name or Former Address, if Changed Since Last Report)

Registrant's telephone number, including area code: +972-4-988-9488

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On June 26, 2007, the Board of Directors of Protalix BioTherapeutics, Inc. (the Company) appointed Ms. Yodfat Harel Gross as a director of the Company. The appointment was made in accordance with Article V, Section 2 of the ByLaws of the Company. Ms. Harel Gross was appointed

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

to serve as a director until the Company's next annual meeting of shareholders and was appointed to serve on the Board of Directors Audit Committee and Compensation Committee.

**Item 8.01. Other Events**

On June 26, 2007, the Company issued a press release announcing that its shares have been added to the broad market Russell 3000(R) Index. The press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 Press release dated June 26, 2007.

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: June 27, 2007

By:           /s/ David Aviezer          

Name: David Aviezer, Ph.D.

Title: President and  
Chief Executive Officer

3

---